Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer

Fernández‐Nogueira, Patricia; Noguera‐Castells, Aleix; Fuster, Gemma; Recalde-Percaz, Leire; Moragas, Núria; López-Plana, Anna; Enreig, Estel; Jáuregui, Patricia; Carbó, Neus; Almendro, Vanessa; Gascón, Pedro; Bragado, Paloma; Mancino, Mario

doi:10.1016/j.canlet.2018.03.014

Cited by 41 publications

(26 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to systemically explore potential ceRNA regulating these hub genes mentioned above, the while its role in breast cancer has not been reported. Existing literature has indicated that HRH1 is correlated with the better prognosis in patients with breast cancer [25]. TMEM132C is reported to be act as the promising diagnostic and prognostic markers in breast cancer [26].…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Identification of a novel lncRNA‑miRNA‑mRNA competing endogenous RNA network associated with prognosis of breast cancer

Wan

Hao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Breast cancer is one of the most common malignant tumors. Recently, the effects of competing endogenous RNA (ceRNA) on molecular biological mechanism of cancer has aroused great interext. However, research on the pathogenesis and biomarkers of breast cancer is still limited. Thus, this study is aimed to identify the competing endogenous RNA (ceRNA) network related to prognosis of patients with breast cancer.Methods: The RNA SEQ data and corresponding clinical information were downloaded from the Cancer Genome Atlas (TCGA) database, and the difference analysis was performed after data quality control.The similarity between two groups of genes with traits in the network was analyzed by weighted correlation network analysis (WGCNA) . Next, the interaction among lncRNA, miRNA, and mRNA was predicted using miRcode, TargetScan, miRDB, and miRTarBase database, and the lncRNA-miRNA-mRNA ceRNA network was constructed. Finally, the survival model of target mRNA was established by Cox regression analysis.Results: In total 5056 differentially expressed lncRNAs, 712 differentially expressed miRNAs, and 9878 differentially expressed mRNAs were identified. WGCNA predicted that 823 lncRNAs and 1813 mRNAs were closely related to the breast cancer. The lncRNA-miRNA-mRNA ceRNA network involved in breast cancer was constructed with 27 lncRNA, 14 miRNAs and 4 mRNAs. The AUC of four survival models of target mRNA (ZC3H12B + HRH1 + TMEM132C + PAG1) was 0.609, which suggested the sensitivity and specificity of prognosis prediction of breast cancer.Conclusion: This study provides insight into the ceRNA network involved in breast cancer biology, which significantly associated with gene regulation and prognosis of breast cancer. BackgroundBreast cancer, the most frequently diagnosed malignancy in women, remains the second reason for cancer-related in female around the world [1]. It is reported that there are three major therapies for breast cancer, including chemotherapy, endocrine therapy, and targeted therapy [2]. Breast cancer, a heterogeneous disease, varies greatly among different patients and even within each individual patient [3]. Although the survival rate has gradually increased due to the early detection and

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Identification of a novel lncRNA‑miRNA‑mRNA competing endogenous RNA network associated with prognosis of breast cancer

Wan

Hao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It is also very well known that the immune system plays a crucial role with respect to the development as well as resolution of malignant lesions. A previous study showed that histamine secreted by mast cells triggers cell proliferation, embryonic development and tumor growth [19]. We found that histamine can induce HeLa cell proliferation by causing abnormal ER signal.…”

Section: Discussionmentioning

confidence: 64%

Apigenin Inhibits Histamine-Induced Cervical Cancer Tumor Growth by Regulating Estrogen Receptor Expression

Zhang

et al. 2020

Molecules

View full text Add to dashboard Cite

Apigenin is a natural flavone with anti-inflammatory and antioxidant properties and antitumor abilities against several types of cancers. Previous studies have found that the antitumor effects of apigenin may be due to its similar chemical structure to 17β-estradiol (E2), a main kind of estrogen in women. However, the precise mechanism underlying the antitumor effects of apigenin in cervical cancer remains unknown. On the other hand, there is increasing evidence that describes a histamine role in cancer cell proliferation. In this study, we examined whether apigenin can attenuate the effects of histamine on tumors by regulating the expression level of estrogen receptors (ERs) to inhibit cervical cancer growth. Our in vitro data indicates that apigenin inhibited cell proliferation in a dose-dependent manner in human cervical cancer cells (HeLa), while histamine shows the opposite effects. After that, the xenograft model was established to explore the antitumor effects of apigenin in vivo, the results show that apigenin inhibited cervical tumor growth by reversing the abnormal ER signal in tumor tissue which was caused by histamine. We also demonstrate that apigenin inhibited cell proliferation via suppressing the PI3K/Akt/mTOR signaling pathway. Collectively, our results suggest that apigenin may inhibit tumor growth through the ER-mediated PI3K/Akt/mTOR pathway and that it can also attenuate the effects of histamine on tumors.

show abstract

“…Terfenadine inhibited proliferation and activated ERK signalling, initiating the mitochondrial apoptotic pathway in vitro . Moreover, in vivo studies demonstrated that terfenadine administration reduced the tumour growth of basal and trastuzumab‐resistant breast cancer cells (Fernández‐Nogueira et al ., 2018). In addition, another H 1 receptor antagonist, astemizole, when combined with histamine induced autophagy and apoptosis targeting p53‐dependent crosstalk in human MCF‐7 breast cancer cells (Jakhar et al ., 2016).…”

Section: Introductionmentioning

confidence: 99%

Histamine receptors and cancer pharmacology: an update

Massari

Nicoud

Medina

2018

British J Pharmacology

View full text Add to dashboard Cite

In the present review, we will discuss the recent advances in the understanding of the role of histamine and histamine receptors in cancer biology. The controversial role of the histaminergic system in different neoplasias including gastric, colorectal, oesophageal, oral, pancreatic, liver, lung, skin, blood and breast cancers will be reviewed. The expression of histamine receptor subtypes, with special emphasis on the histamine H4 receptor, in different cell lines and human tumours, the signal transduction pathways and the associated biological responses as well as the in vivo treatment of experimental tumours with pharmacological ligands will be described. The presented evidence demonstrates that histamine regulates cancer‐associated biological processes during cancer development in multiple cell types, including neoplastic cells and cells in the tumour micro‐environment. The outcome will depend on tumour cell type, the level of expression of histamine receptors, signal transduction associated with these receptors, tumour micro‐environment and histamine metabolism, reinforcing the complexity of cancer disease. Findings show the pivotal role of H4 receptors in the development and progression of many types of cancers, and considering its immunomodulatory properties, the H4 receptor appears to be the most promising molecular therapeutic target for cancer treatment within the histamine receptor family. Furthermore, the H4 receptor is differentially expressed in tumours compared with normal tissues, and in most cancer types in which data are available, H4 receptor expression is associated with clinicopathological characteristics, suggesting that H4 receptors might represent a novel cancer biomarker. Linked Articles This article is part of a themed section on New Uses for 21st Century. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.3/issuetoc

show abstract

Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer

Cited by 41 publications

References 46 publications

WITHDRAWN: Identification of a novel lncRNA‑miRNA‑mRNA competing endogenous RNA network associated with prognosis of breast cancer

WITHDRAWN: Identification of a novel lncRNA‑miRNA‑mRNA competing endogenous RNA network associated with prognosis of breast cancer

Apigenin Inhibits Histamine-Induced Cervical Cancer Tumor Growth by Regulating Estrogen Receptor Expression

Histamine receptors and cancer pharmacology: an update

Contact Info

Product

Resources

About